about
Antigen-specific human NKT cells from tuberculosis patients produce IL-21 to help B cells for the production of immunoglobulinsThe pathogenesis of systemic lupus erythematosus—an updateGenome-wide association study in Asian populations identifies variants in ETS1 and WDFY4 associated with systemic lupus erythematosus.Safety and efficacy of combined cyclophosphamide and rituximab treatment in recalcitrant childhood lupus.The role of B cells in lupus pathogenesis.B cell signature during inactive systemic lupus is heterogeneous: toward a biological dissection of lupus.Germinal center B cell depletion diminishes CD4+ follicular T helper cells in autoimmune miceIncreased levels of prolactin receptor expression correlate with the early onset of lupus symptoms and increased numbers of transitional-1 B cells after prolactin treatmentSimilarities and differences between selective and nonselective BAFF blockade in murine SLEAberrant CD40-induced NF-κB activation in human lupus B lymphocytesMolecular characterization of circulating plasma cells in patients with active systemic lupus erythematosus.Naive CD4 T cells constitutively express CD40L and augment autoreactive B cell survival.Pathogenesis and potential therapeutic targets in systemic lupus erythematosus: from bench to bedsideInfection of Female BWF1 Lupus Mice with Malaria Parasite Attenuates B Cell Autoreactivity by Modulating the CXCL12/CXCR4 Axis and Its Downstream Signals PI3K/AKT, NFκB and ERK.Impact of dietary deviation on disease progression and gut microbiome composition in lupus-prone SNF1 mice.Challenges in bringing the bench to bedside in drug development for SLE.T cells and B cells in lupus nephritis.BLyS antagonists and peptide tolerance induction.BAFF and MyD88 signals promote a lupuslike disease independent of T cells.HDAC expression and activity is upregulated in diseased lupus-prone mice.Human embryonic stem cell-derived mesenchymal cells preserve kidney function and extend lifespan in NZB/W F1 mouse model of lupus nephritisPossible therapeutic applications of single-chain antibodies in systemic autoimmune diseases.Continuous inhibitory signaling by both SHP-1 and SHIP-1 pathways is required to maintain unresponsiveness of anergic B cells.Targeting of the immune system in systemic lupus erythematosus.MicroRNA-let-7a promotes E2F-mediated cell proliferation and NFκB activation in vitro.Interleukin-21 as a potential therapeutic target for systemic lupus erythematosus.Vitamin D3: a helpful immuno-modulator.How important is vitamin D in preventing infections?The Active Metabolite of Vitamin D3 as a Potential Immunomodulator.Current and Emerging Therapies for Lupus Nephritis.Inhibition of a C-rich oligodeoxynucleotide on activation of immune cells in vitro and enhancement of antibody response in mice.Allogenic mesenchymal stem cell transplantation ameliorates nephritis in lupus mice via inhibition of B-cell activation.Plasma cells in systemic lupus erythematosus: the long and short of it all.11th annual Inflammatory and Immune Diseases Drug Discovery and Development Summit 12-13 March 2007, San Francisco, USA.Abnormal B-cell development in Systemic Lupus Erythematosus: what the genetics tell us.Raised expression of cytokine receptor gp130 subunit on peripheral lymphocytes of patients with active lupus. A useful tool for monitoring the disease activity?A tolerogenic peptide down-regulates mature B cells in bone marrow of lupus-afflicted mice by inhibition of interleukin-7, leading to apoptosis.
P2860
Q28386271-D8FD3DA0-B0D4-4D05-97A1-8609008CB631Q29394347-3DE45BF7-F990-42B7-8F2E-F70E7F9490CFQ29417087-F9DB0EC6-D36C-48D9-BE1A-C41CE2EFCBD2Q33411406-6BA078FD-85C1-4233-8DE2-B12DA79ED59AQ33716669-D5F889DD-B08E-4FC4-B5CA-189E02A03FD4Q34009020-ED0F668B-7327-4768-A788-EA86270A824FQ34015403-D22D3873-A8D2-4FB1-84EB-F6A340A3A770Q34190173-D233123A-CF41-4026-8FD2-AD552B84E96FQ34350295-03EDF67E-5F16-4B49-AB77-16C912F9E1D8Q34404682-9059F498-A620-4AF1-AED7-72A5069C8866Q34427053-F88D3459-A2EC-435B-A3A7-79B47D0F0B88Q34702800-E27A6153-1C77-48DD-99C9-8DE06439C038Q35309470-F9F97EEA-0A80-405F-986D-BAD22DCCDE93Q35536652-EE62D97B-9D0A-41B8-8835-ADF42C29FAA1Q35565080-6EADEB71-DED4-4F91-8CD4-52F71057826DQ35968394-477874C7-A05A-43A9-9715-E258B141E9BCQ36019347-4E941DB9-C867-424E-BB70-14652C49C12DQ36088054-BB6EC499-A97F-41ED-B77F-DD928A53D40CQ36229560-5E619D00-6C5F-48AB-9931-B843A69290A4Q36338516-BEEE8910-92BF-4AA1-B155-6F27E73F6436Q36340132-5AAE51B2-91EB-430A-A462-32E7D1CF2D99Q36810295-E42CC864-DAF8-44C9-ABF6-BE788BEE0F2FQ36863105-A4CB56DE-FFD1-4346-9E13-665C84CC2004Q37060593-7ED5F811-6838-474C-9D89-71CD78AA22CFQ37626256-C66265E2-ED91-4020-A3CF-09E204521C92Q37812288-0A30F67B-D0EB-4B28-97AE-E5D35AA7A5F8Q37927252-99D47809-2F33-4110-8CD2-40D4B6986BE3Q38060570-AAA22B55-BA44-449F-AE76-C75A5D7C1BA6Q38672342-B9128AEE-560F-42F8-924D-D2E799D42F44Q38855495-4174E2C0-D0E4-4417-B580-C4A42B6DD5F7Q42964283-37A05F59-CC55-4B24-A95E-2F16B9526187Q44985029-BC82B7F2-CB84-4055-8720-4124A3A828C1Q45938061-596590D8-7A27-43B1-A231-F7FB008C56F8Q46197457-FD555851-7173-4AAA-B0CE-7795AD54FD1BQ47365066-C94C4F12-7785-4C85-BD5A-D6AFA7E8FD43Q51824324-69780911-C617-4863-AA49-1FE40A85657AQ54465969-8CD1E1AE-56EA-4CA7-8681-EA155BC0ED89
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
B cell abnormalities in systemic lupus erythematosus
@ast
B cell abnormalities in systemic lupus erythematosus
@en
type
label
B cell abnormalities in systemic lupus erythematosus
@ast
B cell abnormalities in systemic lupus erythematosus
@en
prefLabel
B cell abnormalities in systemic lupus erythematosus
@ast
B cell abnormalities in systemic lupus erythematosus
@en
P2860
P921
P356
P1476
B cell abnormalities in systemic lupus erythematosus
@en
P2093
Amrie C Grammer
Peter E Lipsky
P2860
P2888
P356
10.1186/AR1009
P478
P577
2003-12-02T00:00:00Z
P5875
P6179
1049554402